Immunotherapeutic Effect of Concholepas Hemocyanin in the Murine Bladder Cancer Model: Evidence for Conserved Antitumor Properties Among Hemocyanins

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2690-2695

  Moltedo, Bruno ^a   Faunes, Fernando ^a   Haussmann, Denise ^a   De Ioannes, Pablo ^a   De Ioannes, Alfredo E ^a   Puente, Javier ^a   Becker, María Inés ^a  

^a Department of Biochemistry and Molecular Biology ^*  (Chile)

Author keywords

bladder; bladder neoplasms; Gastropoda; hemocyanin; immunotherapy

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HEMOCYANIN; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMEDICINE; BLADDER CANCER; BLADDER CARCINOMA; CANCER SURVIVAL; CELL ACTIVITY; CELLULAR IMMUNITY; CONCHOLEPAS CONCHOLEPAS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GASTROPOD; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INCIDENCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GASTROPODA; HEMOCYANIN; MICE; MICE, INBRED C3H; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 33751024089     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.136     Document Type: Article

References (20)

1. Lamm D.L., Dehaven J.I., and Riggs D.R. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol, suppl. 37 (2000) 41
2. Olsson C.A., Chute R., and Rao C.N. Immunologic reduction of bladder cancer recurrence rate. J Urol 111 (1974) 173
3. Jurincic C.D., Engelmann U., Gash J., and Klippel K.F. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 139 (1988) 723
4. Flamm J., Bucher A., Höltl W., and Albrecht W. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial. J Urol 144 (1990) 260
5. Wishahi M.M., Ismail I.M.H., Ruebben H., and Otto T. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality?. Phase II trial: superficial bladder cancer. J Urol 153 (1995) 926
6. Harris J.R., and Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30 (1999) 597
7. De Ioannes P., Moltedo B., Oliva H., Pacheco R., Faunes F., De Ioannes A.E., et al. Hemocyanin of the molluskan Concholepas concholepas exhibits an unusual heterodecameric array of subunits. J Biol Chem 279 (2004) 26134
8. Riggs D.R., DeHaven J.I., and Lamm D.L. Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 79 (1997) 1987
9. Lau B.H.S., Woolley J.L., Marsh C.L., Barker G.R., Koobs D.H., and Torrey R.R. Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma. J Urol 136 (1986) 701
10. Swerdlow R.D., Ratliff T.L., La Regina M., Ritchey J.K., and Ebert R.F. Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model. J Urol 151 (1994) 1718
11. Puente J., Salas M.A., Canon C., Miranda D., Wolf M.E., and Mosnaim A.D. Activation of protein tyrosine kinase: a possible requirement for fixed bacteria and lipopolysaccharide-induced increase in human natural killer cell activity. Int J Clin Pharmacol Ther 34 (1996) 212
12. Jutel M., Watanabe T., Klunker S., Akdis M., Thomet O.A.R., Malolepszy J., et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413 (2001) 420
13. De Boer E.C., Teppema J.S., Steerenberg P.A., and De Jong W.H. Retrovirus type C in the mouse bladder carcinoma cell line MBT-2. J Urol 163 (2000) 1999
14. Günther J.H., Jurczok A., Wulf T., Brandau S., Deinert I., Jocham D., et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59 (1999) 2834
15. Linn J.F., Black P., Derksen K., Rübben H., and Thüroff J.W. Keyhole limpet haemocyanin in experimental bladder cancer. Eur Urol, suppl. 37 (2000) 34
16. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57Bl/10ScCr mice: mutation in TLr4 gene. Science 282 (1998) 2085
17. Jurincic-Winkler C., Metz K.A., Beuth J., Engelman U., and Klippel K.F. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin. Br J Urol 76 (1995) 702
18. Lambert S.L., Okada C.Y., and Levy R. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J Immunol 172 (2004) 929
19. Ikemoto S., Kamizuru M., Wada S., Asai Y., and Kishimoto T. Changes in lymphocytes subsets following administration of interleukin 2 and cyclophosphamide in mice with transitional cell carcinoma. Oncol Res 9 (1997) 71
20. Brandau S., Riemensberger J., Jacobsen M., Kemp D., Zhao W., Zhao X., et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 92 (2001) 697